Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

41.09 +0.18 (+0.43%)
Streaming Delayed Price Updated: 9:52 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gsk Plc ADR

< Previous 1 2 3 Next >
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia 
Via MarketBeat
Exposures Product Safety
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
From GSK plc
Via Business Wire
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
From GSK plc
Via Business Wire
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally 
From Alector, Inc.
Via GlobeNewswire
23andMe Reports Third Quarter Fiscal 2024 Financial Results
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473 
From 23andMe, Inc.
Via GlobeNewswire
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
From GSK plc
Via Business Wire
Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology
From Elegen
Via Business Wire
GSK Enters Agreement to Acquire Aiolos Bio
From Aiolos Bio, Inc.
Via Business Wire
GlaxoSmithKline PLC (NYSE: GSK) Records 52-Week High Monday Morning
Via Investor Brand Network
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
From GSK plc
Via Business Wire
3 cheap 'stock'-ing stuffers Wall Street is bullish on
These three companies have Wall Street feeling bullish and are trading under $10, making them ideal ‘stock'-ing stuffers for hard to shop for traders. 
Via MarketBeat
Topics Stocks
Exposures US Equities
These biotechs targeting multiple neurodegenerative diseases
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
Via MarketBeat
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
From GSK plc
Via Business Wire
GSK is a remedy for the winter investment blahs
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe... 
From 23andMe, Inc.
Via GlobeNewswire
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
From GSK plc
Via Business Wire
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
By David Willey, Benzinga 
Via TheNewswire.com
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
From GSK plc
Via Business Wire
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
From GSK plc
Via Business Wire
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
From GSK plc
Via Business Wire
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
From GSK plc
Via Business Wire
GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US
From GSK plc
Via Business Wire
Drugmaker GSK: Becoming a Healthier Value Stock
Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit. 
Via MarketBeat
Topics Lawsuit
Exposures Financial Legal
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
From GSK plc
Via Business Wire
GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
From GSK plc
Via Business Wire
GSK and Lifetime® Release Short Film Featuring Soleil Moon Frye and Melissa Joan Hart Urging Parents to “Ask2BSure” about Meningitis B
From GSK plc
Via Business Wire
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making... 
Via FinancialNewsMedia
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
From GSK plc
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.